Evidence map›Paper›PMID 32094276›Full record

ArticleJournal of clinical pathology2020

Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID).

Mark James Ponsford, Rachael Steven, Kathyrn Bramhall, Mathew Burgess, Sonali Wijetilleka, Emily Carne, Frances McGuire, Colin R Price, Mo Moody, Soha Zouwail and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Vaccination and clozapine use: a systematic review and an analysis of the VAERS database.European archives of psychiatry and clinical neuroscience · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Management of clozapine treatment during the COVID-19 pandemic.Therapeutic advances in psychopharmacology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Mark James PonsfordImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK ponsfordm@cardiff.ac.uk.ORCID http://orcid.org/0000-0002-0236-1059
Rachael StevenImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Kathyrn BramhallImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Mathew BurgessImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Sonali WijetillekaImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Emily CarneImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Frances McGuireImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Colin R PriceImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Mo MoodyImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Soha ZouwailDepartment of Medical Biochemistry, University Hospital of Wales, Cardiff, UK.
Tayyeb TahirLiaison Psychiatry, University Hospital of Wales, Cardiff, UK.
Daniel FarewellDivision of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK.
Tariq El-ShanawanyImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Stephen R A JollesImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
University Hospital of Wales · GBCardiff University · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

aimsAn association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns.

methodsRetrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunological features for individuals with diagnosis of schizophrenia-like illness.

results1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizoaffective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was noted in 6/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT.

conclusionsOur findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency common variable immunodeficiency, however appears reversible on drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group.

Indexed as

Antipsychotic AgentsB-LymphocytesClozapineCommon Variable ImmunodeficiencyHumansImmunologic Deficiency SyndromesRetrospective StudiesSchizophreniaAntipsychotic AgentsClozapineantibodiesdiagnosticsflow cytometryimmunodeficiencypsychiatry

Identifiers

PMID32094276
PMCPMC7476264
OpenAlexW3008438005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.